

**EPOCRATES® ONLINE****MultiCheck List**

---

carbamazepine  
clarithromycin  
clonazepam  
fluoxetine  
ibuprofen  
lorazepam  
methylprednisolone  
propranolol  
Topamax  
Vicoprofen

**MultiCheck Results**

---

**Avoid/Use Alternative****1. carbamazepine <-> clarithromycin**

use alternative or monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of toxicity (hepatic metab. inhibited)

**2. clarithromycin <-> clonazepam**

use alternative or consider lower benzodiazepine dose: combo may incr. benzodiazepine levels, risk of CNS depression, psychomotor impairment (hepatic metab. inhibited)

**3. ibuprofen <-> propranolol**

monitor BP, consider alternatives: combo may decr. antihypertensive efficacy (antagonistic effect due to NSAID-induced inhibition of renal prostaglandins, sodium and fluid retention)

**4. ibuprofen <-> Vicoprofen**

avoid combo w/ other NSAIDs: combo may incr. risk of GI bleeding, adverse effects (additive effects, duplicate tx)

**5. propranolol <-> Vicoprofen**

monitor BP, consider alternatives: combo may decr. antihypertensive efficacy (antagonistic effect due to NSAID-induced inhibition of renal prostaglandins, sodium and fluid retention)

**Monitor/Modify Tx****6. carbamazepine <-> fluoxetine**

caution advised, monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects; may incr. risk of serotonin syndrome, neuroleptic malignant syndrome (hepatic metab. inhibited; additive effects)

**7. clarithromycin <-> methylprednisolone**

monitor potassium, caution advised: combo may incr. risk of QT prolongation, cardiac arrhythmias; may incr. corticosteroid levels, risk of adverse effects (hypokalemia; hepatic metab. inhibited)

#### **8. fluoxetine <-> propranolol**

monitor BP, HR; consider lower beta blocker dose or non-hepatically metabolized beta blocker: combo may incr. beta blocker levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metab. inhibited)

### **Caution Advised**

#### **9. carbamazepine <-> clonazepam**

caution advised: combo may incr. risk of CNS depression (additive effects)

#### **10. carbamazepine <-> lorazepam**

caution advised: combo may incr. risk of CNS depression (additive effects)

#### **11. carbamazepine <-> methylprednisolone**

caution advised: combo may decr. corticosteroid levels, efficacy (hepatic metab. induced)

#### **12. carbamazepine <-> Topamax**

caution advised: combo may decr. topiramate levels, efficacy (hepatic metab. induced)

#### **13. clonazepam <-> fluoxetine**

caution advised: combo may incr. benzodiazepine levels, risk of CNS depression, psychomotor impairment (hepatic metab. inhibited)

#### **14. clonazepam <-> lorazepam**

caution advised: combo may incr. risk of CNS depression, other adverse effects (additive effects)

#### **15. clonazepam <-> Topamax**

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

#### **16. clonazepam <-> Vicoprofen**

caution advised, interaction more likely w/ IV benzodiazepines and IV opioids: combo may result in vasodilation, severe hypotension, CNS and respiratory depression, psychomotor impairment (additive effects)

#### **17. fluoxetine <-> ibuprofen**

caution advised: combo may incr. risk of bleeding (synergistic effects, NSAID antiplatelet effects augmented by inhibition of platelet serotonin uptake)

#### **18. fluoxetine <-> Vicoprofen**

caution advised: combo w/ ibuprofen may incr. risk of bleeding; combo may decr. hydrocodone efficacy (synergistic effects, NSAID antiplatelet effects augmented by inhibition of platelet serotonin uptake; hepatic metab. inhibited, decr. conversion to active metabolite)

**19. ibuprofen <-> methylprednisolone**

caution advised: combo may incr. risk of GI bleeding, sodium/water retention, edema (additive effects)

**20. lorazepam <-> Topamax**

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

**21. lorazepam <-> Vicoprofen**

caution advised, interaction more likely w/ IV benzodiazepines and IV opioids: combo may result in vasodilation, severe hypotension, CNS and respiratory depression, psychomotor impairment (additive effects)

**22. methylprednisolone <-> Topamax**

caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. corticosteroid levels, efficacy (hepatic metab. induced)

**23. methylprednisolone <-> Vicoprofen**

caution advised: combo may incr. risk of GI bleeding, sodium/water retention, edema (additive effects)

**24. Topamax <-> Vicoprofen**

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

---

Substantial effort has been made to ensure that the information provided by Epocrates is accurate and up-to-date, but this information is not intended to cover all possible uses, precautions, or other considerations relating to the therapies covered. Epocrates does not advocate or endorse the use of any drug or other therapy and does not diagnose patients. Healthcare professionals should use their professional judgment in using this information, and this information should not be considered a substitute for the care and professional judgment provided by a licensed healthcare practitioner. This information is provided on an "as is" basis, and Epocrates and its affiliates, agents and licensors assume no responsibility for any aspect of healthcare administered with the aid of this information or any other use of the information.

© Epocrates, Inc., All Rights Reserved.

Epocrates® Online is a trademark of Epocrates Inc, in the U.S. and elsewhere.